{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-25-000007","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2025-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.680737+00:00","generated_at":"2026-05-27T03:10:17.753281+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Boston Scientific Q4 revenue $4.56B (+22% YoY) beats guidance; adj EPS $0.70; FY25 organic guide 10-12%","bullets":["Q4 net sales $4.561B (+22.4% reported, 19.5% organic); GAAP EPS $0.38, adjusted EPS $0.70 vs guidance $0.64-0.66.","Full year 2024 net sales $16.747B (+17.6% reported); GAAP EPS $1.25, adjusted EPS $2.51.","Cardiovascular segment grew 28.8% reported; U.S. sales up 30.7%.","Guidance: Q1 2025 adj EPS $0.66-0.68, FY 2025 adj EPS $2.80-2.87; organic growth 10-12% for FY.","Completed acquisitions of Axonics and Cortex; announced deals for Bolt Medical and Intera Oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-25-000007","json":"https://secwatch.observer/filing/0000885725-25-000007.json","markdown":"https://secwatch.observer/filing/0000885725-25-000007.md","text":"https://secwatch.observer/filing/0000885725-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000007/0000885725-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572525000007/bsx-20250205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:10:17.753281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}